You looked at the wrong event. the one confused you occurred in Feb.
The one we are talking occurred in may (see below):
Aastrom Biosciences, Inc. Announces FDA Lifts Clinical Hold From Heart Study-Reuters Thursday, 18 Jun 2009 07:51am EDT Reuters reported that Aastrom Biosciences, Inc. said U.S. health regulators removed the clinical hold from the Company's mid-stage trial of a treatment for congestive heart failure. The Company said it would resume patient enrollment at all five initiated clinical sites. The FDA, the clinical site's principal investigator and an independent Data Safety Monitoring Board (DSMB) attributed the patient's death to progression of the disease and determined it was unrelated to the CRC treatment. Aastrom Biosciences, Inc. Places Phase II IMPACT-DCM Clinical Trial On Hold Following Report Of Serious Adverse Event
Friday, 22 May 2009 06:55am EDT Aastrom Biosciences, Inc. announced that it has temporarily suspended enrollment and patient treatment in its U.S. Phase II IMPACT-DCM clinical trial following a report that a patient died at home after being released from the hospital following treatment in the trial. The patient's cause of death has not yet been determined and is the subject of a pending investigation at the clinical site. An independent Data Safety Monitoring Board (DSMB) will also assess the circumstances of the event. In accordance with standard operating procedures, the Company has informed the U.S. Food and Drug Administration (FDA) of the following: the death of the patient after being released from the hospital; the initiation of an investigation into the cause of death; and that the Company has voluntarily suspended patient enrollment and treatment in the trial. Subsequently, the FDA placed the trial on temporary clinical hold pending an investigation. Follow-up of patients previously enrolled in the IMPACT-DCM trial will continue in accordance with study protocol.